Daewoong Pharmaceutical acquires halal certification for 'Easyef' through Daewoong Infion

SEOUL, South Korea and JAKARTA, Indonesia, May 27, 2020 -- Daewoong Pharmaceutical (CEO Sengho Jeon) announced on May 25 that the Indonesian joint venture Daewoong Infion (CEO Chang Woo Suh) obtained Halal certification for the diabetic foot ulcer drug 'Easyef topical solution(Easyef)' from the Indonesian Halal certification agency LPPOM MUI on May 20.

Easyef is Korea's first biologic drug approved by the Korean Ministry of Food and Drug Safety (MFDS) in 2001 for the treatment of diabetic foot ulcer. Daewoong Pharmaceutical has conducted continuous research to upgrade the dosage form of Easyef through Daewoong Infion. In March this year, the integrated dosage form produced originally from Daewoong Infion obtained marketing authorization from the Indonesian National Agency of Drug and Food Control (BPOM) and successfully obtained Halal certification in just 2 months.

Indonesia, which has the largest Muslim population in the world, implemented the Halal Product Law, which mandated companies to indicate whether they have Halal certification for food, cosmetics and drugs, from October 2019. Indonesia's LPPOM MUI is regarded as one of the top 3 Halal certification agencies in the world along with Malaysia's JAKIM and Singapore's MUIS. To obtain certification from LPPOM MUI, it is required to meet strict conditions, including submitting safety documents and receiving site inspection on production and material management processes.